Embolizing chemotherapeutic methods are presently used primarily for nonresectable metastatic hepatic
carcinoma. Because this kind of
carcinoma is generally ischemic, little is expected from embolizing chemotherapeutic methods aimed at
tumor necrosis by blood flow obstruction using
gelatin sponges. On the other hand, since the arrival rate of
Lipiodol is not very good, embolizing chemotherapeutic
therapy employing
Lipiodol is not expected to be very effective. Consequently,
therapies against metastatic hepatic
carcinoma have mainly been intraarterial
chemotherapies without embolization.
Spherex is a transient embolization agent prepared by suspending 60 mg/ml of
degradable starch microspheres (hereinafter, DSM) in physiological saline. It was developed by Pharmacia AB, Sweden, as an arterial embolizing agent for embolizing
chemotherapy, and it was the first agent approved for use in Japan as an embolization material. DSM is composed of spherical particles approx. 45 microns in diameter prepared by crosslinking partially hydrolyzed potato
starch using
epichlorohydrin as a crosslinking agent, and it is characterized by gradual decomposition by blood
amylase, having a half-life of 20-35 minutes in vitro. Clinically, when
Spherex is administered via the arteries, embolization has been found to occur in the arterioles. Furthermore, administration of
Spherex via the hepatic artery in combination with an anticancer
drug results in the formation of transient reduction of bloodflow, thus making it possible to extend the period of retention of the anticancer
drug at a high concentration in the tumorous region. As a result, the local antitumor effect of the anticancer
drug may be reinforced, with alleviation of systemic side effects. In clinical tests involving its administration to metastatic hepatic
tumors in combination with
mitomycin C (hereinafter, MMC), the efficacy is 54.5% with arterial injection
therapy with
Spherex, which is significantly superior to the 20.0% obtained with arterial injection of MMC alone. Although the rate of side effects exhibited, including
pain, digestive symptoms and
fever, has been significantly higher in combination with
Spherex, myelosuppression indicated by abnormal fluctuations in leukocyte and platelet counts was found to be greater with administration of MMC alone, suggesting its value as an effective future
therapy for metastatic hepatic
carcinoma. These data indicate that
Spherex is not expected to yield an antitumor effect due to long-term blood flow obstruction in the hepatic artery, an effect associated with
gelatin sponges heretofore used for embolizing
chemotherapy. Instead, it causes a transient occlusion upon one-shot
intraarterial injection therapy with MMC, thus extending the retention time of MMC at high concentration in tumorous sections, thereby yielding a high local antitumor effect with MMC.(ABSTRACT TRUNCATED AT 400 WORDS)